Claims for Patent: 6,585,995

Summary for Patent: 6,585,995

Title:	Methods and compositions for treating platelet-related disorders
Abstract:	The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
Inventor(s):	Hanson; Stephen R. (Stone Mountain, GA)
Assignee:
Application Number:	09/666,223
Patent Claims:	1. A method for treating a subject to inhibit a vaso-occlusive event comprising administering to a subject in need of such treatment an agent that reduces platelet count in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the subject does not have a hematological proliferative disorder, wherein the agent is not an MPL pathway inhibitory agent. 2. The method of claim 1, wherein subject is treated to inhibit a vaso-occlusive event that is a pathological narrowing or occlusion of a stent, blood vessel, or vascular graft. 3. The method of claim 1, wherein subject is treated to inhibit a vaso-occlusive event that is intimal hyperplasia. 4. The method of claim 1, wherein subject is treated to inhibit a vaso-occlusive event that is a thrombotic event. 5. The method of claim 4, wherein the thrombotic event is a thromboembolic event. 6. The method of claim 4, wherein the thrombotic event is a primary thrombotic event. 7. The method of claim 4, wherein the thrombotic event is a secondary thrombotic event. 8. The method of claim 4, wherein the thrombotic event is selected from the group consisting of arterial thrombosis, coronary thrombosis, venous thrombosis, microvascular thrombosis, stent thrombosis, graft thrombosis and heart valve thrombosis. 9. The method of claim 4, wherein the vaso-occlusive event is selected from the group consisting of myocardial infarction, stroke, transient ischemic attack and coronary stenosis. 10. The method of claim 1, wherein the subject has a normal platelet count prior to treatment. 11. The method of claim 1, wherein the platelet count is reduced to a below normal level. 12. The method of claim 1, wherein the subject has an above normal platelet count prior to treatment. 13. The method of claim 1, wherein the subject is otherwise free of symptoms calling for treatment with the agent. 14. The method of claim 1, wherein the subject is apparently healthy. 15. The method of claim 1, wherein the subject exhibits symptoms of a vaso-occlusive event. 16. The method of claim 1, wherein the subject is a human. 17. The method of claim 1, wherein the subject has an abnormally elevated risk of a thrombotic event. 18. The method of claim 1, wherein the subject has vascular disease. 19. The method of claim 18, wherein the vascular disease is selected from the group consisting of arteriosclerosis, cardiovascular disease, cerebrovascular disease, renovascular disease, mesenteric vascular disease, pulmonary vascular disease, ocular vascular disease and peripheral vascular disease. 20. The method of claim 1, wherein the subject has had a primary vaso-occlusive event. 21. The method of claim 1, wherein the subject has a condition selected from the group consisting of hypercholesterolemia, hypertension and atherosclerosis. 22. The method of claim 1, wherein the subject will undergo an elective surgical procedure. 23. The method of claim 1, wherein the subject has undergone a surgical procedure. 24. The method of claim 22, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement and vascular stenting. 25. The method of claim 23, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement and vascular stenting. 26. The method of claim 1, wherein the effective amount is in the range of 30 .mu.g/kg/day to 150 .mu.g/kg/day. 27. The method of claim 1, wherein the effective amount is in the range of 1 .mu.g/kg/day to 150 .mu.g/kg/day. 28. The method of claim 1, wherein the agent is administered for at least one week. 29. The method of claim 1, wherein platelet count is reduced by at least 10%. 30. The method of claim 1, wherein platelet count is reduced by at least 20%. 31. The method of claim 1, wherein platelet count is reduced by at least 50%. 32. The method of claim 1, wherein platelet count is reduced to below 200.times.10.sup.3 platelets per .mu.l. 33. The method of claim 1, wherein platelet count is reduced to below 150.times.10.sup.3 platelets per .mu.l. 34. The method of claim 1, wherein platelet count is reduced to below 100.times.10.sup.3 platelets per .mu.l. 35. The method of claim 1, wherein platelet count is reduced by at least 10% and to above 200.times.10.sup.3 per .mu.l. 36. The method of claim 1, wherein the agent is administered with an agent for treating vascular disease or complication. 37. The method of claim 36, wherein the agent for treating vascular disease or complication is an anti-thrombotic agent. 38. The method of claim 37, wherein the anti-thrombotic agent is selected from the group consisting of anti-coagulant agents, fibrinolytic agents and inhibitors of platelet function. 39. The method of claim 38, wherein the inhibitors of platelet function are selected from the group consisting of aspirin, abciximab, clopidogrel and dipyridamole. 40. The method of claim 38, wherein the anti-coagulant agents are selected from the group consisting of glycosoaminoglycans and vitamin K antagonists. 41. The method of claim 38, wherein the fibrinolytic agents are selected from the group consisting of plasminogen activators, plasmin and plasminogen. 42. The method of claim 41, wherein the plasminogen activators are selected from the group consisting of tissue plasminogen activator (TPA), streptokinase and urokinase. 43. The method of claim 22, wherein the agent is administered prior to the elective surgery. 44. The method of claim 1, wherein the agent is administered by a parenteral route. 45. The method of claim 1, wherein the agent is administered by an enteral route. 46. The method of claim 1, wherein the agent is administered in a sustained release device. 47. The method of claim 20, wherein the agent is administered following the primary vaso-occlusive event. 48. A method for treating a subject to inhibit a vaso-occlusive event comprising administering to a subject in need of such treatment an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the agent is administered for at least thirty days, and wherein the agent is not an MPL pathway inhibitory agent. 49. A method for treating a subject to inhibit a vaso-occlusive event comprising administering to a subject in need of such treatment an agent that reduces platelet count in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the subject does not have a hematological proliferative disorder, and wherein the agent is anagrelide or a derivative thereof. 50. The method of claim 49, wherein subject is treated to inhibit a vaso-occlusive event that is a pathological narrowing or occlusion of a stent, blood vessel, or vascular graft. 51. The method of claim 49, wherein subject is treated to inhibit a vaso-occlusive event that is intimal hyperplasia. 52. The method of claim 49, wherein subject is treated to inhibit a vaso-occlusive event that is a thrombotic event. 53. The method of claim 52, wherein the thrombotic event is a thromboembolic event. 54. The method of claim 52, wherein the thrombotic event is a primary thrombotic event. 55. The method of claim 52, wherein the thrombotic event is a secondary thrombotic event. 56. The method of claim 52, wherein the thrombotic event is selected from the group consisting of arterial thrombosis, coronary thrombosis, venous thrombosis, microvascular thrombosis, stent thrombosis, graft thrombosis and heart valve thrombosis. 57. The method of claim 52, wherein the vaso-occlusive event is selected from the group consisting of myocardial infarction, stroke, transient ischemic attack and coronary stenosis. 58. The method of claim 49, wherein the subject has a normal platelet count prior to treatment. 59. The method of claim 49, wherein the platelet count is reduced to a below normal level. 60. The method of claim 49, wherein the subject has an above normal platelet count prior to treatment. 61. The method of claim 49, wherein the subject is otherwise free of symptoms calling for treatment with the agent. 62. The method of claim 49, wherein the subject is apparently healthy. 63. The method of claim 49, wherein the subject exhibits symptoms of a vaso-occlusive event. 64. The method of claim 49, wherein the subject is a human. 65. The method of claim 49, wherein the subject has an abnormally elevated risk of a thrombotic event. 66. The method of claim 49, wherein the subject has vascular disease. 67. The method of claim 66, wherein the vascular disease is selected from the group consisting of arteriosclerosis, cardiovascular disease, cerebrovascular disease, renovascular disease, mesenteric vascular disease, pulmonary vascular disease, ocular vascular disease and peripheral vascular disease. 68. The method of claim 49, wherein the subject has had a primary vaso-occlusive event. 69. The method of claim 49, wherein the subject has a condition selected from the group consisting of hypercholesterolemia, hypertension and atherosclerosis. 70. The method of claim 49, wherein the subject will undergo an elective surgical procedure. 71. The method of claim 49, wherein the subject has undergone a surgical procedure. 72. The method of claim 70, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement and vascular stenting. 73. The method of claim 71, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement and vascular stenting. 74. The method of claim 49, wherein the effective amount is in the range of 30 .mu.g/kg/day to 150 .mu.g/kg/day. 75. The method of claim 49, wherein the effective amount is in the range of 1 .mu.g/kg/day to 150 .mu.g/kg/day. 76. The method of claim 49, wherein the agent is administered for at least one week. 77. The method of claim 49, wherein platelet count is reduced by at least 10%. 78. The method of claim 49, wherein platelet count is reduced by at least 20%. 79. The method of claim 49, wherein platelet count is reduced by at least 50%. 80. The method of claim 49, wherein platelet count is reduced to below 200.times.10.sup.3 platelets per .mu.l. 81. The method of claim 49, wherein platelet count is reduced to below 150.times.10.sup.3 platelets per .mu.l. 82. The method of claim 49, wherein platelet count is reduced to below 100.times.10.sup.3 platelets per .mu.l. 83. The method of claim 49, wherein platelet count is reduced by at least 10% and to above 200.times.10.sup.3 per .mu.l. 84. The method of claim 49, wherein the agent is administered with an agent for treating vascular disease or complication. 85. The method of claim 84, wherein the agent for treating vascular disease or complication is an anti-thrombotic agent. 86. The method of claim 85, wherein the anti-thrombotic agent is selected from the group consisting of anti-coagulant agents, fibrinolytic agents and inhibitors of platelet function. 87. The method of claim 86, wherein the inhibitors of platelet function are selected from the group consisting of aspirin, abciximab, clopidogrel and dipyridamole. 88. The method of claim 86, wherein the anti-coagulant agents are selected from the group consisting of glycosoaminoglycans and vitamin K antagonists. 89. The method of claim 86, wherein the fibrinolytic agents are selected from the group consisting of plasminogen activators, plasmin and plasminogen. 90. The method of claim 89, wherein the plasminogen activators are selected from the group consisting of tissue plasminogen activator (TPA), streptokinase and urokinase. 91. The method of claim 70, wherein the agent is administered prior to the elective surgery. 92. The method of claim 49, wherein the agent is administered by a parenteral route. 93. The method of claim 49, wherein the agent is administered by an enteral route. 94. The method of claim 49, wherein the agent is administered in a sustained release device. 95. The method of claim 68, wherein the agent is administered following the primary vaso-occlusive event. 96. A method for treating a subject to inhibit a vaso-occlusive event comprising administering to a subject in need of such treatment an agent that reduces platelet counts in the subject in an amount effective to reduce platelet count in the subject to at least a low normal level, wherein the agent is administered for at least thirty days; and wherein the agent is anagrelide or a derivative thereof.

Details for Patent 6,585,995

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2019-09-21
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2019-09-21